Drotrecogin alfa

Drug Profile

Drotrecogin alfa

Alternative Names: DrotAA; LTC-203; LY 203638; Recombinant human activated protein C; rhAPC; Xigris

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Georgetown University; Syncor; Teijin Pharma
  • Class Anticoagulants; Antithrombotics; Blood proteins; Enzyme precursors; Recombinant proteins
  • Mechanism of Action Fibrinolytic agents; Serine endopeptidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Septic shock
  • Discontinued Thrombosis

Most Recent Events

  • 25 Oct 2011 Discontinued - Phase-I for Septic shock in Japan (IV)
  • 25 Oct 2011 Discontinued - Registered for Septic shock in Colombia (IV)
  • 25 Oct 2011 Discontinued - Registered for Septic shock in Peru (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top